Sab Biotherapeutics Stock Analysis

SABS Stock  USD 3.15  0.08  2.48%   
SAB Biotherapeutics is overvalued with Real Value of 2.7 and Target Price of 2.3. The main objective of SAB Biotherapeutics stock analysis is to determine its intrinsic value, which is an estimate of what SAB Biotherapeutics is worth, separate from its market price. There are two main types of SAB Biotherapeutics' stock analysis: fundamental analysis and technical analysis.
The SAB Biotherapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. SAB Biotherapeutics is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. SAB Stock trading window is adjusted to America/New York timezone.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

SAB Stock Analysis Notes

About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.75. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. SAB Biotherapeutics recorded a loss per share of 6.72. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 5th of January 2024. SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about SAB Biotherapeutics contact the company at 605 679 6980 or learn more at

SAB Biotherapeutics Investment Alerts

SAB Biotherapeutics generated a negative expected return over the last 90 days
SAB Biotherapeutics has high historical volatility and very poor performance
SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (12.53 M).
SAB Biotherapeutics currently holds about 16.62 M in cash with (25.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
SAB Biotherapeutics has a frail financial position based on the latest SEC disclosures
Roughly 19.0% of the company outstanding shares are owned by corporate insiders
Latest headline from BVF Inc. IL Acquires New Stake in SAB Biotherapeutics, Inc. - Defense World

SAB Biotherapeutics Upcoming and Recent Events

12th of February 2024
Upcoming Quarterly Report
21st of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
12th of February 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

SAB Largest EPS Surprises

Earnings surprises can significantly impact SAB Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

SAB Biotherapeutics Environmental, Social, and Governance (ESG) Scores

SAB Biotherapeutics' ESG score is a quantitative measure that evaluates SAB Biotherapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of SAB Biotherapeutics' operations that may have significant financial implications and affect SAB Biotherapeutics' stock price as well as guide investors towards more socially responsible investments.

SAB Stock Institutional Investors

Blackrock Inc2024-03-31
6.3 K
Advisor Group Holdings, Inc.2024-03-31
4.5 K
Tower Research Capital Llc2024-03-31
1.4 K
Morgan Stanley - Brokerage Accounts2024-03-31
1.2 K
Spectrum Wealth Counsel Llc2024-03-31
Princeton Global Asset Management Llc2024-03-31
Gs Investment Inc2024-03-31
Jpmorgan Chase & Co2024-03-31
Wells Fargo & Co2024-03-31
Rtw Investments, Llc2024-03-31
917.8 K
Bvf Inc2024-03-31
917.8 K
Note, although SAB Biotherapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

SAB Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.07 M.

SAB Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.50)(0.53)
Return On Capital Employed(0.52)(0.55)
Return On Assets(0.50)(0.53)
Return On Equity(0.74)(0.70)

Management Efficiency

SAB Biotherapeutics has return on total asset (ROA) of (0.4611) % which means that it has lost $0.4611 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0325) %, meaning that it created substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2024. Return On Capital Employed is likely to drop to -0.55 in 2024. At this time, SAB Biotherapeutics' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 2.7 M in 2024, whereas Total Assets are likely to drop slightly above 63.5 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 10.38  7.50 
Tangible Book Value Per Share 10.38  7.50 
Enterprise Value Over EBITDA 0.37  0.39 
Price Book Value Ratio 0.66  0.70 
Enterprise Value Multiple 0.37  0.39 
Price Fair Value 0.66  0.70 
Enterprise Value-12.7 M-12 M
The analysis of SAB Biotherapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze SAB Biotherapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of SAB Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
Return On Assets
Return On Equity

Technical Drivers

As of the 18th of June 2024, SAB Biotherapeutics owns the Market Risk Adjusted Performance of 2.27, information ratio of (0.10), and Coefficient Of Variation of (1,039). In respect to fundamental indicators, the technical analysis model makes it possible for you to check possible technical drivers of SAB Biotherapeutics, as well as the relationship between them. Please validate SAB Biotherapeutics mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if SAB Biotherapeutics is priced fairly, providing market reflects its prevailing price of 3.15 per share. Given that SAB Biotherapeutics has information ratio of (0.10), we advise you to double-check SAB Biotherapeutics's latest market performance to make sure the company can sustain itself in the future.

SAB Biotherapeutics Price Movement Analysis

Execute Study
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. SAB Biotherapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for SAB Biotherapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

SAB Biotherapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SAB Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SAB Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SAB Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

SAB Biotherapeutics Predictive Daily Indicators

SAB Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SAB Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

SAB Biotherapeutics Corporate Filings

31st of May 2024
Report filed with the SEC to announce major events that shareholders should know about
30th of May 2024
Other Reports
21st of May 2024
Report filed with the SEC to announce major events that shareholders should know about
20th of May 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
15th of May 2024
Other Reports
14th of May 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
8th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
15th of April 2024
Report filed with the SEC to announce major events that shareholders should know about

SAB Biotherapeutics Forecast Models

SAB Biotherapeutics' time-series forecasting models are one of many SAB Biotherapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary SAB Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About SAB Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how SAB Biotherapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling SAB shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as SAB Biotherapeutics. By using and applying SAB Stock analysis, traders can create a robust methodology for identifying SAB entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(18.85)(17.90)
Operating Profit Margin(17.01)(16.16)
Net Loss(18.85)(17.90)
Gross Profit Margin(0.67)(0.64)

Current SAB Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. SAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. SAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.3Strong Buy3Odds
SAB Biotherapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most SAB analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand SAB stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of SAB Biotherapeutics, talking to its executives and customers, or listening to SAB conference calls.
SAB Analyst Advice Details

SAB Stock Analysis Indicators

SAB Biotherapeutics stock analysis indicators help investors evaluate how SAB Biotherapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading SAB Biotherapeutics shares will generate the highest return on investment. By understating and applying SAB Biotherapeutics stock analysis, traders can identify SAB Biotherapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow15 M
Common Stock Shares Outstanding5.5 M
Total Stockholder Equity57.3 M
Quarterly Earnings Growth Y O Y-0.6
Property Plant And Equipment Net24.7 M
Cash And Short Term Investments56.6 M
Cash56.6 M
Accounts Payable945.9 K
Net Debt-50.7 M
50 Day M A3.7447
Total Current Liabilities10.8 M
Other Operating Expenses40.3 M
Non Current Assets Total25 M
Non Currrent Assets Other350.2 K
Stock Based Compensation2.4 M

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.